LIVIVO - Das Suchportal für Lebenswissenschaften

switch to English language
Zurück zur letzten Suche Suchhistorie
Erweiterte Suche

Ihre letzten Suchen

  1. AU="Bhambhani, Chandan"
  2. AU="Hage, J Joris"
  3. AU="Nonaka, Manabu"
  4. AU=Murray Alan T
  5. AU="Rajput, Shatruhan Singh"
  6. AU="Galati, A"
  7. AU="Shakhuro, Vlad"
  8. AU="Jayatilleke, S"
  9. AU="Dalal, Jamshed J"
  10. AU="Lashley, Maudry-Beverley"
  11. AU="Jeffers, Scott"
  12. AU="Durairaj, Janani"
  13. AU="Shu, Yixiong"
  14. AU="Prieto, Franklin"
  15. AU="Attwood, Matthew J"
  16. AU=Andellini Martina
  17. AU=Ilfeld Brian M
  18. AU="Manuel de Villena, Fernando Pardo"
  19. AU=Anand B S
  20. AU="Pandeya, Sarbesh R"
  21. AU="Parra Viviane M."
  22. AU="Anetsberger, Daniel"
  23. AU="Novizio, Nunzia"
  24. AU="Elizabeth Sweeney"
  25. AU="Carrigan, M"
  26. AU="Majid T Noghani"
  27. AU="Hanh, Bui Thi Bich"
  28. AU="Hyun Chul Song"
  29. AU="Cottraux, Jean"
  30. AU=Mauro Michael J
  31. AU="Labate, Demetrio"
  32. AU=Ahmad S

Suchergebnis

Treffer 1 - 10 von insgesamt 13

Suchoptionen

  1. Artikel: Trans-Renal Cell-Free Tumor DNA for Urine-Based Liquid Biopsy of Cancer.

    Dermody, Sarah M / Bhambhani, Chandan / Swiecicki, Paul L / Brenner, J Chad / Tewari, Muneesh

    Frontiers in genetics

    2022  Band 13, Seite(n) 879108

    Abstract: Cancer biomarkers are a promising tool for cancer detection, personalization of therapy, and monitoring of treatment response or recurrence. "Liquid biopsy" commonly refers to minimally invasive or non-invasive sampling of a bodily fluid (i.e., blood, ... ...

    Abstract Cancer biomarkers are a promising tool for cancer detection, personalization of therapy, and monitoring of treatment response or recurrence. "Liquid biopsy" commonly refers to minimally invasive or non-invasive sampling of a bodily fluid (i.e., blood, urine, saliva) for detection of cancer biomarkers such as circulating tumor cells or cell-free tumor DNA (ctDNA). These methods offer a means to collect frequent tumor assessments without needing surgical biopsies. Despite much progress with blood-based liquid biopsy approaches, there are limitations-including the limited amount of blood that can be drawn from a person and challenges with collecting blood samples at frequent intervals to capture ctDNA biomarker kinetics. These limitations are important because ctDNA is present at extremely low levels in plasma and there is evidence that measuring ctDNA biomarker kinetics over time can be useful for clinical prediction. Additionally, blood-based assays require access to trained phlebotomists and often a trip to a healthcare facility. In contrast, urine is a body fluid that can be self-collected from a patient's home, at frequent intervals, and mailed to a laboratory for analysis. Multiple reports indicate that fragments of ctDNA pass from the bloodstream through the kidney's glomerular filtration system into the urine, where they are known as trans-renal ctDNA (TR-ctDNA). Accumulating studies indicate that the limitations of blood based ctDNA approaches for cancer can be overcome by measuring TR-ctDNA. Here, we review current knowledge about TR-ctDNA in urine as a cancer biomarker approach, and discuss its clinical potential and open questions in this research field.
    Sprache Englisch
    Erscheinungsdatum 2022-04-27
    Erscheinungsland Switzerland
    Dokumenttyp Journal Article ; Review
    ZDB-ID 2606823-0
    ISSN 1664-8021
    ISSN 1664-8021
    DOI 10.3389/fgene.2022.879108
    Datenquelle MEDical Literature Analysis and Retrieval System OnLINE

    Zusatzmaterialien

    Kategorien

    Über subito bestellen

    Dieser Service ist kostenpflichtig (siehe Lieferbedingungen von subito). Bestellungen, die einen Artikel nebst Supplementary Material umfassen, werden grundsätzlich wie mehrfache Bestellungen bearbeitet. Gebühren fallen in diesen Fällen für jede einzelne Bestellung an.

  2. Artikel ; Online: Surveillance and Monitoring Techniques for HPV-Related Head and Neck Squamous Cell Carcinoma: Circulating Tumor DNA.

    Dermody, Sarah M / Haring, Catherine T / Bhambhani, Chandan / Tewari, Muneesh / Brenner, J Chad / Swiecicki, Paul L

    Current treatment options in oncology

    2021  Band 22, Heft 3, Seite(n) 21

    Abstract: Opinion statement: Human papilloma virus (HPV) related head and neck cancer is rising in prevalence, preferentially affecting young patients and imparting long term toxicities. Despite this, there are no screening tests or clinical biomarkers for ... ...

    Abstract Opinion statement: Human papilloma virus (HPV) related head and neck cancer is rising in prevalence, preferentially affecting young patients and imparting long term toxicities. Despite this, there are no screening tests or clinical biomarkers for treatment monitoring. HPV circulating tumor DNA (HPV ctDNA) represents a novel circulating biomarker which may provide real-time assessment of tumor response to therapy and recurrence. Early work suggests the promise of this assay as a predictive biomarker in numerous clinical settings, namely risk of recurrence after chemoradiation in locally advanced disease. Advancement of these findings to the clinic will require a collaborative effort in the field, including technical harmonization of assay testing characteristics, understanding of the normal kinetics in patients being treated with standard of care therapies, and appropriately designed phase III trials prior to implementation in the clinic. If successful, HPV ctDNA has the potential to revolutionize clinical trial treatment paradigms and transform patient care.
    Mesh-Begriff(e) Animals ; Biomarkers, Tumor ; Cell-Free Nucleic Acids ; Combined Modality Therapy ; DNA, Neoplasm ; Disease Management ; Disease Susceptibility ; Early Detection of Cancer/methods ; Humans ; Liquid Biopsy/methods ; Molecular Diagnostic Techniques ; Papillomaviridae ; Papillomavirus Infections/complications ; Papillomavirus Infections/virology ; Prognosis ; Squamous Cell Carcinoma of Head and Neck/diagnosis ; Squamous Cell Carcinoma of Head and Neck/etiology ; Squamous Cell Carcinoma of Head and Neck/metabolism ; Squamous Cell Carcinoma of Head and Neck/therapy ; Treatment Outcome
    Chemische Substanzen Biomarkers, Tumor ; Cell-Free Nucleic Acids ; DNA, Neoplasm
    Sprache Englisch
    Erscheinungsdatum 2021-02-08
    Erscheinungsland United States
    Dokumenttyp Journal Article ; Review
    ZDB-ID 2057351-0
    ISSN 1534-6277 ; 1527-2729
    ISSN (online) 1534-6277
    ISSN 1527-2729
    DOI 10.1007/s11864-021-00821-8
    Datenquelle MEDical Literature Analysis and Retrieval System OnLINE

    Volltext online

    Zusatzmaterialien

    Kategorien

    Verfügbar in ZB MED Köln/Königswinter

    Zs.A 5523: Hefte anzeigen Standort:
    Je nach Verfügbarkeit (siehe Angabe bei Bestand)
    bis Jg. 1994: Bestellungen von Artikeln über das Online-Bestellformular
    Jg. 1995 - 2021: Lesesall (2.OG)
    ab Jg. 2022: Lesesaal (EG)

    Über subito bestellen

    Dieser Service ist kostenpflichtig (siehe Lieferbedingungen von subito). Bestellungen, die einen Artikel nebst Supplementary Material umfassen, werden grundsätzlich wie mehrfache Bestellungen bearbeitet. Gebühren fallen in diesen Fällen für jede einzelne Bestellung an.

  3. Artikel ; Online: Development of a high-performance multi-probe droplet digital PCR assay for high-sensitivity detection of human papillomavirus circulating tumor DNA from plasma.

    Bhambhani, Chandan / Sandford, Erin / Haring, Catherine T / Brummel, Collin / Tuck, Kirsten L / Olesnavich, Mary / Bhangale, Apurva D / Walline, Heather M / Dermody, Sarah M / Spector, Matthew E / Chinn, Steven B / Casper, Keith / Mierzwa, Michelle / Swiecicki, Paul L / Chad Brenner, J / Tewari, Muneesh

    Oral oncology

    2023  Band 143, Seite(n) 106436

    Abstract: Objectives: To develop a high-performance droplet digital PCR (ddPCR) assay capable of enhancing the detection of human papillomavirus (HPV) circulating tumor DNA (ctDNA) in plasma from patients with HPV-associated oropharyngeal squamous cell carcinoma ( ...

    Abstract Objectives: To develop a high-performance droplet digital PCR (ddPCR) assay capable of enhancing the detection of human papillomavirus (HPV) circulating tumor DNA (ctDNA) in plasma from patients with HPV-associated oropharyngeal squamous cell carcinoma (HPV+ OPSCC).
    Materials and methods: Plasma samples from subjects with HPV+ OPSCC were collected. We developed a high-performance ddPCR assay designed to simultaneously target nine regions of the HPV16 genome.
    Results: The new assay termed 'ctDNA HPV16 Assessment using Multiple Probes' (CHAMP- 16) yielded significantly higher HPV16 counts compared to our previously validated 'Single-Probe' (SP) assay and a commercially available NavDx® assay. Analytical validation demonstrated that the CHAMP-16 assay had a limit of detection (LoD) of 4.1 copies per reaction, corresponding to < 1 genome equivalent (GE) of HPV16. When tested on plasma ctDNA from 21 patients with early-stage HPV+ OPSCC and known HPV16 ctDNA using the SP assay, all patients were positive for HPV16 ctDNA in both assays and the CHAMP-16 assay displayed 6.6-fold higher HPV16 signal on average. Finally, in a longitudinal analysis of samples from a patient with recurrent disease, the CHAMP-16 assay detected HPV16 ctDNA signal ∼ 20 months prior to the conventional SP assay.
    Conclusion: Increased HPV16 signal detection using the CHAMP-16 assay suggests the potential for detection of recurrences significantly earlier than with conventional ddPCR assays in patients with HPV16+ OPSCC. Critically, this multi-probe approach maintains the cost-benefit advantage of ddPCR over next generation sequencing (NGS) approaches, supporting the cost-effectiveness of this assay for both large population screening and routine post-treatment surveillance.
    Mesh-Begriff(e) Humans ; Circulating Tumor DNA ; Human Papillomavirus Viruses ; Carcinoma, Squamous Cell/pathology ; Papillomavirus Infections ; Human papillomavirus 16/genetics ; Polymerase Chain Reaction ; Head and Neck Neoplasms ; Oropharyngeal Neoplasms
    Chemische Substanzen Circulating Tumor DNA
    Sprache Englisch
    Erscheinungsdatum 2023-06-01
    Erscheinungsland England
    Dokumenttyp Journal Article
    ZDB-ID 1120465-5
    ISSN 1879-0593 ; 0964-1955 ; 1368-8375
    ISSN (online) 1879-0593
    ISSN 0964-1955 ; 1368-8375
    DOI 10.1016/j.oraloncology.2023.106436
    Datenquelle MEDical Literature Analysis and Retrieval System OnLINE

    Volltext online

    Zusatzmaterialien

    Kategorien

    Verfügbar in ZB MED Köln/Königswinter

    Zs.A 4869: Hefte anzeigen Standort:
    Je nach Verfügbarkeit (siehe Angabe bei Bestand)
    bis Jg. 1994: Bestellungen von Artikeln über das Online-Bestellformular
    Jg. 1995 - 2021: Lesesall (2.OG)
    ab Jg. 2022: Lesesaal (EG)
    Zs.A 456: Hefte anzeigen Standort:
    Je nach Verfügbarkeit (siehe Angabe bei Bestand)
    bis Jg. 1994: Bestellungen von Artikeln über das Online-Bestellformular
    Jg. 1995 - 2021: Lesesall (1.OG)
    ab Jg. 2022: Lesesaal (EG)

    Über subito bestellen

    Dieser Service ist kostenpflichtig (siehe Lieferbedingungen von subito). Bestellungen, die einen Artikel nebst Supplementary Material umfassen, werden grundsätzlich wie mehrfache Bestellungen bearbeitet. Gebühren fallen in diesen Fällen für jede einzelne Bestellung an.

  4. Artikel ; Online: ctDNA transiting into urine is ultrashort and facilitates noninvasive liquid biopsy of HPV+ oropharyngeal cancer.

    Bhambhani, Chandan / Kang, Qing / Hovelson, Daniel H / Sandford, Erin / Olesnavich, Mary / Dermody, Sarah M / Wolfgang, Jenny / Tuck, Kirsten L / Brummel, Collin / Bhangale, Apurva D / He, Kuang / Gutierrez, Marc G / Lindstrom, Ryan H / Liu, Chia-Jen / Tuck, Melissa / Kandarpa, Malathi / Mierzwa, Michelle / Casper, Keith / Prince, Mark E /
    Krauss, John C / Talpaz, Moshe / Henry, N Lynn / Giraldez, Maria D / Ramnath, Nithya / Tomlins, Scott A / Swiecicki, Paul L / Brenner, J Chad / Tewari, Muneesh

    JCI insight

    2024  Band 9, Heft 6

    Abstract: BACKGROUNDTransrenal cell-free tumor DNA (TR-ctDNA), which transits from the bloodstream into urine, has the potential to enable noninvasive cancer detection for a wide variety of nonurologic cancer types.MethodsUsing whole-genome sequencing, we ... ...

    Abstract BACKGROUNDTransrenal cell-free tumor DNA (TR-ctDNA), which transits from the bloodstream into urine, has the potential to enable noninvasive cancer detection for a wide variety of nonurologic cancer types.MethodsUsing whole-genome sequencing, we discovered that urine TR-ctDNA fragments across multiple cancer types are predominantly ultrashort (<50 bp) and, therefore, likely to be missed by conventional ctDNA assays. We developed an ultrashort droplet digital PCR assay to detect TR-ctDNA originating from HPV-associated oropharyngeal squamous cell carcinoma (HPV+ OPSCC) and confirmed that assaying ultrashort DNA is critical for sensitive cancer detection from urine samples.ResultsTR-ctDNA was concordant with plasma ctDNA for cancer detection in patients with HPV+ OPSCC. As proof of concept for using urine TR-ctDNA for posttreatment surveillance, in a small longitudinal case series, TR-ctDNA showed promise for noninvasive detection of recurrence of HPV+ OPSCC.ConclusionOur data indicate that focusing on ultrashort fragments of TR-ctDNA will be important for realizing the full potential of urine-based cancer diagnostics. This has implications for urine-based detection of a wide variety of cancer types and for facilitating access to care through at-home specimen collections.FundingNIH grants R33 CA229023, R21 CA225493; NIH/National Cancer Institute grants U01 CA183848, R01 CA184153, and P30CA046592; American Cancer Society RSG-18-062-01-TBG; American Cancer Society Mission Boost grant MBGI-22-056-01-MBG; and the A. Alfred Taubman Medical Research Institute.
    Mesh-Begriff(e) United States ; Humans ; Papillomavirus Infections/genetics ; Carcinoma, Squamous Cell/diagnosis ; Carcinoma, Squamous Cell/genetics ; Carcinoma, Squamous Cell/metabolism ; Oropharyngeal Neoplasms/diagnosis ; Oropharyngeal Neoplasms/genetics ; Squamous Cell Carcinoma of Head and Neck ; DNA, Neoplasm ; Head and Neck Neoplasms ; Liquid Biopsy
    Chemische Substanzen DNA, Neoplasm
    Sprache Englisch
    Erscheinungsdatum 2024-02-08
    Erscheinungsland United States
    Dokumenttyp Journal Article
    ISSN 2379-3708
    ISSN (online) 2379-3708
    DOI 10.1172/jci.insight.177759
    Datenquelle MEDical Literature Analysis and Retrieval System OnLINE

    Zusatzmaterialien

    Kategorien

    Über subito bestellen

    Dieser Service ist kostenpflichtig (siehe Lieferbedingungen von subito). Bestellungen, die einen Artikel nebst Supplementary Material umfassen, werden grundsätzlich wie mehrfache Bestellungen bearbeitet. Gebühren fallen in diesen Fällen für jede einzelne Bestellung an.

    Fernleihe an ZB MED

    Sie können sich den gewünschten Titel als lokale Nutzerin oder lokaler Nutzer von ZB MED direkt an den Standort Köln schicken lassen.

  5. Artikel: SARS-CoV-2 Total and Subgenomic RNA Viral Load in Hospitalized Patients.

    Dimcheff, Derek E / Valesano, Andrew L / Rumfelt, Kalee E / Fitzsimmons, William J / Blair, Christopher / Mirabelli, Carmen / Petrie, Joshua G / Martin, Emily T / Bhambhani, Chandan / Tewari, Muneesh / Lauring, Adam S

    medRxiv : the preprint server for health sciences

    2021  

    Abstract: Understanding viral load in patients infected with SARS-CoV-2 is critical to epidemiology and infection control. Previous studies have demonstrated that SARS-CoV-2 RNA can be detected for many weeks after symptom onset. The clinical significance of this ... ...

    Abstract Understanding viral load in patients infected with SARS-CoV-2 is critical to epidemiology and infection control. Previous studies have demonstrated that SARS-CoV-2 RNA can be detected for many weeks after symptom onset. The clinical significance of this finding is unclear and, in most patients, likely does not represent active infection. There are, however, patients who shed infectious virus for weeks. Detection of subgenomic RNA transcripts expressed by SARS-CoV-2 has been proposed to represent productive infection and may be a tractable marker for monitoring infectivity. Here, we use RT-PCR to quantify total and subgenomic nucleocapsid (N) and envelope (E) transcripts in 190 SARS-CoV-2 positive samples collected on hospital admission. We relate these findings to duration of symptoms. We find that all transcripts decline at the same rate; however, subgenomic E becomes undetectable before other transcripts. In Kaplan-Meier analysis the median duration of symptoms to a negative test is 14 days for sgE and 25 days for sgN. There is a linear decline in subgenomic RNA compared to total RNA suggesting subgenomic transcript copy number is highly dependent on copy number of total transcripts. The mean difference between total N and subgenomic N is 16-fold (4.0 cycles) and the mean difference between total E and sub-genomic E is 137-fold (7.1 cycles). This relationship is constant over duration of symptoms allowing prediction of subgenomic copy number from total copy number. Although Subgenomic E is undetectable at a time that may more closely reflect the duration of infectivity, its utility in determining active infection may be no more useful than a copy number threshold determined for total transcripts.
    Sprache Englisch
    Erscheinungsdatum 2021-03-01
    Erscheinungsland United States
    Dokumenttyp Preprint
    DOI 10.1101/2021.02.25.21252493
    Datenquelle MEDical Literature Analysis and Retrieval System OnLINE

    Zusatzmaterialien

    Kategorien

    Fernleihe an ZB MED

    Sie können sich den gewünschten Titel als lokale Nutzerin oder lokaler Nutzer von ZB MED direkt an den Standort Köln schicken lassen.

  6. Artikel ; Online: Severe Acute Respiratory Syndrome Coronavirus 2 Total and Subgenomic RNA Viral Load in Hospitalized Patients.

    Dimcheff, Derek E / Valesano, Andrew L / Rumfelt, Kalee E / Fitzsimmons, William J / Blair, Christopher / Mirabelli, Carmen / Petrie, Joshua G / Martin, Emily T / Bhambhani, Chandan / Tewari, Muneesh / Lauring, Adam S

    The Journal of infectious diseases

    2021  Band 224, Heft 8, Seite(n) 1287–1293

    Abstract: Background: Previous studies demonstrated that severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) RNA can be detected for weeks after infection. The significance of this finding is unclear and, in most patients, does not represent active ... ...

    Abstract Background: Previous studies demonstrated that severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) RNA can be detected for weeks after infection. The significance of this finding is unclear and, in most patients, does not represent active infection. Detection of subgenomic RNA has been proposed to represent productive infection and may be a useful marker for monitoring infectivity.
    Methods: We used quantitative reverse-transcription polymerase chain reaction (RT-qPCR) to quantify total and subgenomic nucleocapsid (sgN) and envelope (sgE) transcripts in 185 SARS-CoV-2-positive nasopharyngeal swab samples collected on hospital admission and to relate to symptom duration.
    Results: We find that all transcripts decline at the same rate; however, sgE becomes undetectable before other transcripts. The median duration of symptoms to a negative test is 14 days for sgE and 25 days for sgN. There is a linear decline in subgenomic compared to total RNA, suggesting that subgenomic transcript copy number is dependent on copy number of total transcripts. The mean difference between total and sgN is 16-fold and the mean difference between total and sgE is 137-fold. This relationship is constant over duration of symptoms, allowing prediction of subgenomic copy number from total copy number.
    Conclusions: Subgenomic RNA may be no more useful in determining infectivity than a copy number threshold determined for total RNA.
    Mesh-Begriff(e) Aged ; COVID-19/diagnosis ; COVID-19/transmission ; COVID-19/virology ; COVID-19 Nucleic Acid Testing/methods ; COVID-19 Nucleic Acid Testing/standards ; COVID-19 Nucleic Acid Testing/statistics & numerical data ; Coronavirus Envelope Proteins/genetics ; Coronavirus Nucleocapsid Proteins/genetics ; Feasibility Studies ; Female ; Humans ; Male ; Middle Aged ; Nasopharynx/pathology ; Nasopharynx/virology ; Phosphoproteins/genetics ; RNA, Viral/isolation & purification ; Real-Time Polymerase Chain Reaction/statistics & numerical data ; Reference Values ; Retrospective Studies ; SARS-CoV-2/genetics ; SARS-CoV-2/isolation & purification ; SARS-CoV-2/pathogenicity ; Viral Load
    Chemische Substanzen Coronavirus Envelope Proteins ; Coronavirus Nucleocapsid Proteins ; Phosphoproteins ; RNA, Viral ; envelope protein, SARS-CoV-2 ; nucleocapsid phosphoprotein, SARS-CoV-2
    Sprache Englisch
    Erscheinungsdatum 2021-04-18
    Erscheinungsland United States
    Dokumenttyp Journal Article ; Research Support, N.I.H., Extramural ; Research Support, Non-U.S. Gov't ; Research Support, U.S. Gov't, P.H.S.
    ZDB-ID 3019-3
    ISSN 1537-6613 ; 0022-1899
    ISSN (online) 1537-6613
    ISSN 0022-1899
    DOI 10.1093/infdis/jiab215
    Datenquelle MEDical Literature Analysis and Retrieval System OnLINE

    Volltext online

    Zusatzmaterialien

    Kategorien

    Verfügbar in ZB MED Köln/Königswinter

    Uh II Zs.50: Hefte anzeigen Standort:
    Je nach Verfügbarkeit (siehe Angabe bei Bestand)
    bis Jg. 2021: Bestellungen von Artikeln über das Online-Bestellformular
    ab Jg. 2022: Lesesaal (EG)
    Zs.MO 445: Hefte anzeigen

    Über subito bestellen

    Dieser Service ist kostenpflichtig (siehe Lieferbedingungen von subito). Bestellungen, die einen Artikel nebst Supplementary Material umfassen, werden grundsätzlich wie mehrfache Bestellungen bearbeitet. Gebühren fallen in diesen Fällen für jede einzelne Bestellung an.

  7. Artikel ; Online: Human papilloma virus circulating tumor DNA assay predicts treatment response in recurrent/metastatic head and neck squamous cell carcinoma.

    Haring, Catherine T / Bhambhani, Chandan / Brummel, Collin / Jewell, Brittany / Bellile, Emily / Heft Neal, Molly E / Sandford, Erin / Spengler, Ryan M / Bhangale, Apurva / Spector, Matthew E / McHugh, Jonathan / Prince, Mark E / Mierzwa, Michelle / Worden, Francis P / Tewari, Muneesh / Swiecicki, Paul L / Brenner, J Chad

    Oncotarget

    2021  Band 12, Heft 13, Seite(n) 1214–1229

    Abstract: Despite the rising incidence of human papillomavirus related (HPV+) oropharyngeal squamous cell carcinoma (OPSCC), treatment of metastatic disease remains palliative. Even with new treatments such as immunotherapy, response rates are low and can be ... ...

    Abstract Despite the rising incidence of human papillomavirus related (HPV+) oropharyngeal squamous cell carcinoma (OPSCC), treatment of metastatic disease remains palliative. Even with new treatments such as immunotherapy, response rates are low and can be delayed, while even mild tumor progression in the face of an ineffective therapy can lead to rapid death. Real-time biomarkers of response to therapy could improve outcomes by guiding early change of therapy in the metastatic setting. Herein, we developed and analytically validated a new droplet digital PCR (ddPCR)-based assay for HPV16 circulating tumor DNA (ctDNA) and evaluated plasma HPV16 ctDNA for predicting treatment response in metastatic HPV+ OPSCC. We found that longitudinal changes HPV16 ctDNA correlate with treatment response and that ctDNA responses are observed earlier than conventional imaging (average 70 days, range: 35-166). With additional validation in multi-site studies, this assay may enable early identification of treatment failure, allowing patients to be directed promptly toward clinical trials or alternative therapies.
    Sprache Englisch
    Erscheinungsdatum 2021-06-22
    Erscheinungsland United States
    Dokumenttyp Journal Article
    ZDB-ID 2560162-3
    ISSN 1949-2553 ; 1949-2553
    ISSN (online) 1949-2553
    ISSN 1949-2553
    DOI 10.18632/oncotarget.27992
    Datenquelle MEDical Literature Analysis and Retrieval System OnLINE

    Zusatzmaterialien

    Kategorien

    Über subito bestellen

    Dieser Service ist kostenpflichtig (siehe Lieferbedingungen von subito). Bestellungen, die einen Artikel nebst Supplementary Material umfassen, werden grundsätzlich wie mehrfache Bestellungen bearbeitet. Gebühren fallen in diesen Fällen für jede einzelne Bestellung an.

  8. Artikel ; Online: SARS-CoV-2 Total and Subgenomic RNA Viral Load in Hospitalized Patients

    Dimcheff, Derek E. / Valesano, Andrew L. / Rumfelt, Kalee E. / Fitzsimmons, William J. / Blair, Christopher / Mirabelli, Carmen / Petrie, Joshua G. / Martin, Emily T. / Bhambhani, Chandan / Tewari, Muneesh / Lauring, Adam S.

    medRxiv

    Abstract: Understanding viral load in patients infected with SARS-CoV-2 is critical to epidemiology and infection control. Previous studies have demonstrated that SARS-CoV-2 RNA can be detected for many weeks after symptom onset. The clinical significance of this ... ...

    Abstract Understanding viral load in patients infected with SARS-CoV-2 is critical to epidemiology and infection control. Previous studies have demonstrated that SARS-CoV-2 RNA can be detected for many weeks after symptom onset. The clinical significance of this finding is unclear and, in most patients, likely does not represent active infection. There are, however, patients who shed infectious virus for weeks. Detection of subgenomic RNA transcripts expressed by SARS-CoV-2 has been proposed to represent productive infection and may be a tractable marker for monitoring infectivity. Here, we use RT-PCR to quantify total and subgenomic nucleocapsid (N) and envelope (E) transcripts in 190 SARS-CoV-2 positive samples collected on hospital admission. We relate these findings to duration of symptoms. We find that all transcripts decline at the same rate; however, subgenomic E becomes undetectable before other transcripts. In Kaplan-Meier analysis the median duration of symptoms to a negative test is 14 days for sgE and 25 days for sgN. There is a linear decline in subgenomic RNA compared to total RNA suggesting subgenomic transcript copy number is highly dependent on copy number of total transcripts. The mean difference between total N and subgenomic N is 16-fold (4.0 cycles) and the mean difference between total E and sub-genomic E is 137-fold (7.1 cycles). This relationship is constant over duration of symptoms allowing prediction of subgenomic copy number from total copy number. Although Subgenomic E is undetectable at a time that may more closely reflect the duration of infectivity, its utility in determining active infection may be no more useful than a copy number threshold determined for total transcripts.
    Schlagwörter covid19
    Sprache Englisch
    Erscheinungsdatum 2021-03-01
    Verlag Cold Spring Harbor Laboratory Press
    Dokumenttyp Artikel ; Online
    DOI 10.1101/2021.02.25.21252493
    Datenquelle COVID19

    Volltext online

    Kategorien

    Fernleihe an ZB MED

    Sie können sich den gewünschten Titel als lokale Nutzerin oder lokaler Nutzer von ZB MED direkt an den Standort Köln schicken lassen.

  9. Artikel ; Online: The oligomeric state of CtBP determines its role as a transcriptional co-activator and co-repressor of Wingless targets.

    Bhambhani, Chandan / Chang, Jinhee L / Akey, David L / Cadigan, Ken M

    The EMBO journal

    2011  Band 30, Heft 10, Seite(n) 2031–2043

    Abstract: C-terminal-binding protein (CtBP) is a well-characterized transcriptional co-repressor that requires homo-dimerization for its activity. CtBP can both repress and activate Wingless nuclear targets in Drosophila. Here, we examine the role of CtBP ... ...

    Abstract C-terminal-binding protein (CtBP) is a well-characterized transcriptional co-repressor that requires homo-dimerization for its activity. CtBP can both repress and activate Wingless nuclear targets in Drosophila. Here, we examine the role of CtBP dimerization in these opposing processes. CtBP mutants that cannot dimerize are able to promote Wingless signalling, but are defective in repressing Wingless targets. To further test the role of dimerization in repression, the positions of basic and acidic residues that form inter-molecular salt bridges in the CtBP dimerization interface were swapped. These mutants cannot homo-dimerize and are compromised for repression. However, their co-expression leads to hetero-dimerization and consequent repression of Wingless targets. Our results support a model where CtBP is a gene-specific regulator of Wingless signalling, with some targets requiring CtBP dimers for inhibition while other targets utilize CtBP monomers for activation of their expression. Functional interactions between CtBP and Pygopus, a nuclear protein required for Wingless signalling, support a model where monomeric CtBP acts downstream of Pygopus in activating some Wingless targets.
    Mesh-Begriff(e) Alcohol Oxidoreductases/genetics ; Alcohol Oxidoreductases/metabolism ; Animals ; Co-Repressor Proteins/metabolism ; DNA-Binding Proteins/genetics ; DNA-Binding Proteins/metabolism ; Drosophila/genetics ; Drosophila/physiology ; Drosophila Proteins/biosynthesis ; Gene Expression Regulation ; Models, Biological ; Mutant Proteins/genetics ; Mutant Proteins/metabolism ; Protein Multimerization ; Transcription Factors/metabolism ; Wnt1 Protein/biosynthesis
    Chemische Substanzen Co-Repressor Proteins ; DNA-Binding Proteins ; Drosophila Proteins ; Mutant Proteins ; Transcription Factors ; Wnt1 Protein ; wg protein, Drosophila ; Alcohol Oxidoreductases (EC 1.1.-) ; C-terminal binding protein (EC 1.1.1.-)
    Sprache Englisch
    Erscheinungsdatum 2011-04-05
    Erscheinungsland England
    Dokumenttyp Journal Article ; Research Support, N.I.H., Extramural ; Research Support, U.S. Gov't, Non-P.H.S.
    ZDB-ID 586044-1
    ISSN 1460-2075 ; 0261-4189
    ISSN (online) 1460-2075
    ISSN 0261-4189
    DOI 10.1038/emboj.2011.100
    Datenquelle MEDical Literature Analysis and Retrieval System OnLINE

    Volltext online

    Zusatzmaterialien

    Kategorien

    Verfügbar in ZB MED Köln/Königswinter

    Zs.A 1808: Hefte anzeigen Standort:
    Je nach Verfügbarkeit (siehe Angabe bei Bestand)
    bis Jg. 1994: Bestellungen von Artikeln über das Online-Bestellformular
    Jg. 1995 - 2021: Lesesall (1.OG)
    ab Jg. 2022: Lesesaal (EG)
    Zs.MG 100: Hefte anzeigen

    Über subito bestellen

    Dieser Service ist kostenpflichtig (siehe Lieferbedingungen von subito). Bestellungen, die einen Artikel nebst Supplementary Material umfassen, werden grundsätzlich wie mehrfache Bestellungen bearbeitet. Gebühren fallen in diesen Fällen für jede einzelne Bestellung an.

  10. Artikel ; Online: Early HPV ctDNA Kinetics and Imaging Biomarkers Predict Therapeutic Response in p16+ Oropharyngeal Squamous Cell Carcinoma.

    Cao, Yue / Haring, Catherine T / Brummel, Collin / Bhambhani, Chandan / Aryal, Madhava / Lee, Choonik / Heft Neal, Molly / Bhangale, Apurva / Gu, Wenjin / Casper, Keith / Malloy, Kelly / Sun, Yilun / Shuman, Andrew / Prince, Mark E / Spector, Matthew E / Chinn, Steven / Shah, Jennifer / Schonewolf, Caitlin / McHugh, Jonathan B /
    Mills, Ryan E / Tewari, Muneesh / Worden, Francis P / Swiecicki, Paul L / Mierzwa, Michelle / Brenner, J Chad

    Clinical cancer research : an official journal of the American Association for Cancer Research

    2021  Band 28, Heft 2, Seite(n) 350–359

    Abstract: Purpose: In locally advanced p16+ oropharyngeal squamous cell carcinoma (OPSCC), (i) to investigate kinetics of human papillomavirus (HPV) circulating tumor DNA (ctDNA) and association with tumor progression after chemoradiation, and (ii) to compare the ...

    Abstract Purpose: In locally advanced p16+ oropharyngeal squamous cell carcinoma (OPSCC), (i) to investigate kinetics of human papillomavirus (HPV) circulating tumor DNA (ctDNA) and association with tumor progression after chemoradiation, and (ii) to compare the predictive value of ctDNA to imaging biomarkers of MRI and FDG-PET.
    Experimental design: Serial blood samples were collected from patients with AJCC8 stage III OPSCC (
    Results: Low pretreatment ctDNA and an early increase in ctDNA at week 2 compared with baseline were significantly associated with superior FFP (
    Conclusions: Early ctDNA kinetics during definitive chemoradiation may predict therapy response in stage III OPSCC.
    Mesh-Begriff(e) Alphapapillomavirus ; Biomarkers ; Carcinoma, Squamous Cell/diagnostic imaging ; Carcinoma, Squamous Cell/genetics ; Carcinoma, Squamous Cell/therapy ; Circulating Tumor DNA/genetics ; Fluorodeoxyglucose F18 ; Head and Neck Neoplasms ; Humans ; Kinetics ; Oropharyngeal Neoplasms/diagnostic imaging ; Oropharyngeal Neoplasms/genetics ; Oropharyngeal Neoplasms/therapy ; Papillomaviridae/genetics ; Papillomavirus Infections/complications ; Papillomavirus Infections/genetics ; Prognosis ; Retrospective Studies ; Squamous Cell Carcinoma of Head and Neck
    Chemische Substanzen Biomarkers ; Circulating Tumor DNA ; Fluorodeoxyglucose F18 (0Z5B2CJX4D)
    Sprache Englisch
    Erscheinungsdatum 2021-10-26
    Erscheinungsland United States
    Dokumenttyp Journal Article ; Randomized Controlled Trial ; Research Support, N.I.H., Extramural
    ZDB-ID 1225457-5
    ISSN 1557-3265 ; 1078-0432
    ISSN (online) 1557-3265
    ISSN 1078-0432
    DOI 10.1158/1078-0432.CCR-21-2338
    Datenquelle MEDical Literature Analysis and Retrieval System OnLINE

    Zusatzmaterialien

    Kategorien

    Verfügbar in ZB MED Köln/Königswinter

    Zs.A 4223: Hefte anzeigen Standort:
    Je nach Verfügbarkeit (siehe Angabe bei Bestand)
    bis Jg. 1994: Bestellungen von Artikeln über das Online-Bestellformular
    Jg. 1995 - 2021: Lesesall (2.OG)
    ab Jg. 2022: Lesesaal (EG)

    Über subito bestellen

    Dieser Service ist kostenpflichtig (siehe Lieferbedingungen von subito). Bestellungen, die einen Artikel nebst Supplementary Material umfassen, werden grundsätzlich wie mehrfache Bestellungen bearbeitet. Gebühren fallen in diesen Fällen für jede einzelne Bestellung an.

Zum Seitenanfang